- Home
- CMMB vs HOOK Comparison
CMMB vs HOOK Comparison
Compare CMMB & HOOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- HOOK
- Stock Information
- Founded
- CMMB 2004
- HOOK 2011
- Country
- CMMB Israel
- HOOK United States
- Employees
- CMMB N/A
- HOOK N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- HOOK Biotechnology: Pharmaceutical Preparations
- Sector
- CMMB Health Care
- HOOK Health Care
- Exchange
- CMMB Nasdaq
- HOOK Nasdaq
- Market Cap
- CMMB 27.0M
- HOOK 30.2M
- IPO Year
- CMMB N/A
- HOOK 2019
- Fundamental
- Price
- CMMB $1.65
- HOOK $2.15
- Analyst Decision
- CMMB Strong Buy
- HOOK Strong Buy
- Analyst Count
- CMMB 3
- HOOK 4
- Target Price
- CMMB $7.33
- HOOK $38.75
- AVG Volume (30 Days)
- CMMB 106.7K
- HOOK 70.1K
- Earning Date
- CMMB 11-14-2024
- HOOK 11-14-2024
- Dividend Yield
- CMMB N/A
- HOOK N/A
- EPS Growth
- CMMB N/A
- HOOK N/A
- EPS
- CMMB N/A
- HOOK N/A
- Revenue
- CMMB N/A
- HOOK $49,999,000.00
- Revenue This Year
- CMMB N/A
- HOOK $155.36
- Revenue Next Year
- CMMB N/A
- HOOK N/A
- P/E Ratio
- CMMB N/A
- HOOK N/A
- Revenue Growth
- CMMB N/A
- HOOK 143.30
- 52 Week Low
- CMMB $0.42
- HOOK $2.08
- 52 Week High
- CMMB $2.55
- HOOK $11.30
- Technical
- Relative Strength Index (RSI)
- CMMB 55.47
- HOOK 14.14
- Support Level
- CMMB $1.55
- HOOK $3.58
- Resistance Level
- CMMB $1.73
- HOOK $3.84
- Average True Range (ATR)
- CMMB 0.16
- HOOK 0.28
- MACD
- CMMB 0.01
- HOOK -0.13
- Stochastic Oscillator
- CMMB 52.83
- HOOK 3.60
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of antigen-specific killer T cells and antibodies.